Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Are Hedge Funds Out to Lunch on Gevo, Inc. (GEVO)?

Page 1 of 2

It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the future holds and how market participants will react to the bountiful news that floods in each day. The S&P 500 Index gained 5.2% in the 12 month-period that ended October 30, while less than 49% of its stocks beat the benchmark. In contrast, the 30 most popular S&P 500 stocks among the hedge fund investors tracked by the Insider Monkey team returned 9.5% over the same period, which provides evidence that these money managers do have great stock picking abilities. Even more to that, 63% of these stocks managed to beat the S&P 500 Index. That’s why we believe it isn’t a waste of time to check out hedge fund sentiment before you invest in a stock like Gevo, Inc. (NASDAQ:GEVO).

Gevo, Inc. (NASDAQ:GEVO) shareholders have witnessed an increase in support from the world’s most elite money managers lately. A brutal 47% fall in the stock during the third quarter was just what smart money needed to take up more positions, as 11 investment firms that we track were long Gevo on September 30, up by one during the quarter, while the value of their holdings ballooned by nearly 500% as smart money pounced on the wounded stock, hoarding 38.40% of its shares as of the end of September. However, shares have continued to decline, not delivering the reversal that smart money may have been expecting. At the end of this article we will also compare GEVO to other stocks including AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), EnteroMedics Inc (NASDAQ:ETRM), and Biodel Inc (NASDAQ:BIOD) to get a better sense of its popularity.

Follow Gevo Inc. (NASDAQ:GEVO)
Trade (NASDAQ:GEVO) Now!

To most investors, hedge funds are viewed as underperforming, outdated investment tools of yesteryear. While there are greater than an 8,000 funds trading at the moment, our researchers look at the masters of this group, approximately 700 funds. These investment experts administer the lion’s share of the hedge fund industry’s total asset base, and by following their best equity investments, Insider Monkey has discovered several investment strategies that have historically outperformed the broader indices. Insider Monkey’s small-cap hedge fund strategy outperformed the S&P 500 index by 12 percentage points per year for a decade in their back tests.

Keeping this in mind, let’s take a peek at the new action encompassing Gevo, Inc. (NASDAQ:GEVO).

What have hedge funds been doing with Gevo, Inc. (NASDAQ:GEVO)?

Heading into Q4, a total of 7 of the hedge funds tracked by Insider Monkey held long positions in this stock, a 17% rise from one quarter earlier. With hedge funds’ sentiment swirling, there exists a select group of notable hedge fund managers who were boosting their stakes considerably (or had already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Hal Mintz’s Sabby Capital has the biggest position in Gevo, Inc. (NASDAQ:GEVO), worth close to $9.8 million, amounting to 0.4% of its total 13F portfolio. Coming in second is Rob Romero’s Connective Capital Management, with a $0.3 million position; 0.6% of its 13F portfolio is allocated to the stock. Other hedge funds and institutional investors that are bullish include Alexander Mitchell’s Scopus Asset Management, and Anand Parekh’s Alyeska Investment Group.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!